ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle invasive bladder ...

In a study of 25 patients undergoing radical cystectomy for bladder cancer, tissue analyses revealed that lower TLR4 ...

A prospective study of 79 bladder cancer patients found that intracorporeal ileal conduit creation significantly reduced ...

Outcomes of Patients Who Declined Radical Cystectomy / cancer, cancer care, Cancer research, cancer treatment, ...

There are patients with muscle-invasive bladder cancer who want to keep their bladder. To what extent did ASTRO support TMT (trimodal therapy), which uses TURBT and chemoradiotherapy instead of ...

( NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of ...

Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today ...

Radical cystectomy is the recommended treatment for patients with BCG-unresponsive NMIBC. However, many patients are ...

An ad hoc analysis from the KEYNOTE-905/EV-303 study showed greater improvements in survival outcomes and response rates in ...

In this exclusive roundtable video from MedPage Today, three expert leaders in the field of bladder cancer discuss the latest ...

( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...